ArticleRespiratory research2026
Delineating a reference interval for functional alpha-1 antitrypsin in the serum of healthy Pi*MM donors using an anti-neutrophil elastase capacity assay.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlpha-1 antitrypsin deficiency (AATD) is a genetic disease resulting in decreased circulating functional levels of alpha-1 antitrypsin (AAT), an important protease inhibitor that protects tissue, particularly the lungs, from protease-mediated degradation. Individuals with AATD-associated emphysema have historically been treated with plasma-derived AAT, requiring weekly infusions. A recombinant AAT-Fc fusion protein, efdoralprin alfa, is currently being studied in clinical trials. Here, we sought to delineate a normal range of functional AAT (fAAT) that can be used to assess how effectively therapies restore fAAT to the normal range.
methodsSelf-reported healthy individuals from Massachusetts were recruited to serve as donors to delineate a reference interval (RI), with requirements for ≥ 75% of individuals to be White. The Mayo Clinic analyzed blood samples from each donor to confirm wildtype Pi*MM phenotype and assess total AAT protein levels using the A1ALC test and a Siemens nephelometry assay, respectively. Samples were assessed for fAAT at BioAgilytix using a validated anti-neutrophil elastase capacity assay with WHO International AAT standards. Verification cohorts were recruited from geographically distinct regions (Florida and California) to confirm that the Massachusetts cohort was representative of the broader population.
resultsOf 237 individual donors in the RI cohort, 211 with confirmed wildtype Pi*MM phenotype were used to calculate the RI. The central 95% range (2.5th percentile to 97.5th percentile) of fAAT concentration was 23.8-42.4 µM, with 23.8 µM designated as the lower limit of normal (LLN). Although one of the Florida verification cohorts was not included because of inability to verify sample-handling procedures, the LLN determined from the RI cohort was in alignment with the other two verification cohorts. In addition, the lower bound for total AAT protein from the RI cohort was 106 mg/dL. This value was consistent with two larger published datasets, supporting the representativeness of the RI cohort.
conclusionsThe fAAT RI and LLN delineated by this study can be applied directly to clinical trials to evaluate the pharmacodynamic effect of AATD therapies, and, in conjunction with clinical trial pharmacokinetic data, can be used to support dosing decisions for patients with AATD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.